Navigation Links
Roche Launches EMR Interface for VA to Facilitate Diabetes Management
Date:4/18/2011

INDIANAPOLIS, April 18, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has introduced a new Electronic Medical Record (EMR) interface for the U.S. Department of Veterans Affairs (VA) that helps VA healthcare facilities improve their efficiency and accuracy by transmitting patient diabetes management data directly into the VistA computerized patient record system (CPRS).

The new JResultNet™ middleware module from Dawning Technologies Inc. enables VA providers to transfer patient blood glucose test results automatically and securely to their EMR from the ACCU-CHEK® 360 Diabetes Management System, a tool designed to help physicians and patients manage diabetes in an outpatient setting. Dawning is a leading supplier of connectivity solutions to the clinical laboratory market.

"This integration package allows any provider within the VA's healthcare system to access a patient's glucose test results, and it offers them a much easier, more accurate way to capture the information and deliver it to the patient's EMR," said Keith Snyder, director of marketing at Roche Diagnostics Corporation. "It has already been successfully implemented at several VA sites, and is contributing to improved efficiency levels."

The JResultNet middleware module delivers test results from the ACCU-CHEK 360 system to the VistA system as an HL7-based TIU (text integration utility) connection – a standard component of the VistA system. The enhanced connectivity helps reduce the potential for errors and helps increase workflow efficiency for the healthcare provider.

About Diabetes and the VADiabetes impacts over 20 percent of VA patients, representing more than 1 million veterans at any given time, and that number continues to rise. The cost of treating complications from diabetes is significant, with one diabetes-related heart attack estimated to cost over $14,000.  The VA's diabetes programs are focused on reducing preventable morbidity and mortality.  Providing secure, automated access to patient glucose results for the entire healthcare team can help facilitate the achievement of that goal.

About Dawning Technologies Inc.Dawning Technologies Inc. is a leading supplier of connectivity solutions to the clinical laboratory market. In business since 1984, Dawning solutions are installed in over 4,000 client sites worldwide. Their customers include information system vendors, IVD instrument manufacturers, POC system vendors and clinical laboratories of all forms. Dawning solutions are available for nearly all clinical analyzers, POC and system-to-system connections. For more information contact their web site at www.dawning.com.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

ACCU-CHEK is a trademark of Roche. Please note that a degree symbol follows the name ACCU-CHEK 360 but is not included due to limitations of website symbol translation capabilities. JResultNet is a trademark of Dawning Technologies. All trademarks used or mentioned in this release are protected by law.For further information, please contact: Betsy CoxDirector, Corporate CommunicationsRoche Diagnostics CorporationIndianapolis, IN(317) 521-3911betsy.cox@roche.com
'/>"/>

SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Completes Acquisition of Laprolan
2. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
3. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
4. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
5. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
6. Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD
7. Rochester Medical Reports First Quarter Results and Recent Developments
8. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
9. Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
10. Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients
11. Rochester Medical Reports Fourth Quarter and Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):